VolitionRx

Update in progress

VNRX (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

VolitionRx Limited is a multinational epigenetics company developing blood tests to detect and monitor cancers and NETosis-related diseases. Operating in the United States, Europe, and Asia, it offers Nu.Q Vet for cancer screening in dogs and other animals; Nu.Q Nets for NETosis-related conditions such as sepsis; Nu.Q Discover for nucleosome profiling; Nu.Q Cancer to predict and monitor treatment response and disease progression; and Capture-PCR/Capture-Seq to isolate circulating tumor DNA from plasma for early detection. Based in Henderson, Nevada.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive